Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIAXIN vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Acute bacterial exacerbation of chronic bronchitis,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Helicobacter pylori eradication (as part of triple or dual therapy),Mycobacterium avium complex prophylaxis and treatment (off-label for some indications)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Primarily metabolized by CYP3A4 isoenzyme; clarithromycin undergoes first-pass metabolism to form 14-hydroxyclarithromycin (active metabolite).
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
65-75% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Vd: 2.6-3.5 L/kg. Clinical meaning: Large Vd indicates extensive tissue penetration, including lungs, tonsils, and sinuses, exceeding serum concentrations.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral bioavailability: 50-55% (250 mg tablet); may be increased to 60-70% when administered with food. Intravenous: 100%.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Cr Cl <30 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: not recommended; no adjustment for Cr Cl >30 m L/min
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh Class C: reduce dose by 50% or consider alternative; mild to moderate hepatic impairment: no adjustment
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
15 mg/kg/day orally divided every 12 hours; maximum 500 mg/day for 10 days; for extended-release, not recommended for children <12 years
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
No specific dose adjustment; monitor renal function and adjust per renal guidelines; increased risk of QT prolongation
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
None
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Increased risk of cardiac arrhythmias, including QT prolongation and torsades de pointes; avoid in patients with known QT prolongation or concurrent use with QT-prolonging drugs.,Potential for hepatotoxicity (elevated liver enzymes, hepatitis); monitor liver function.,Exacerbation of myasthenia gravis symptoms.,Clostridioides difficile-associated diarrhea (CDAD).,Drug interactions via CYP3A4 inhibition (e.g., statins, warfarin, colchicine, and other macrolides).,Pregnancy Category C; avoid use unless no alternative (clarithromycin associated with increased risk of miscarriage and fetal abnormalities in animal studies).
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.,Concurrent use with pimozide, ergotamine, dihydroergotamine, lovastatin, simvastatin, or colchicine in renal/hepatic impairment.,History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.,QT prolongation or history of ventricular arrhythmias (including torsades de pointes).,Concurrent use with antiarrhythmics (e.g., quinidine, procainamide, amiodarone) or other QT-prolonging drugs.,Severe hepatic failure or acute porphyria.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and may increase clarithromycin levels, raising risk of QT prolongation. High-fat meals may delay absorption but do not significantly alter total exposure. Alcohol is not specifically contraindicated but may increase gastrointestinal irritation; avoid concurrent use of statins (especially simvastatin, lovastatin) due to increased myopathy risk.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First trimester: Avoid unless benefit justifies risk. Second and third trimesters: Limited data; use only if clearly needed. Monitor for potential maternal hepatotoxicity.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Clarithromycin is excreted into human breast milk; the milk-to-plasma ratio is approximately 0.25-0.5. Infants exposed via breast milk may experience gastrointestinal disturbances or altered gut flora. Use with caution, especially in infants younger than 6 weeks of age due to risk of hypertrophic pyloric stenosis. Consider temporary discontinuation during therapy if high doses are used.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No specific pharmacokinetic studies have demonstrated a need for dose adjustment during pregnancy. However, pregnancy can increase volume of distribution and renal clearance; empirical dose monitoring is not required. Standard dosing regimens are applied unless hepatic or renal impairment is present.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
Biaxin (clarithromycin) is a macrolide antibiotic with activity against atypical pathogens (e.g., Legionella, Mycoplasma, Chlamydia). It is a potent CYP3A4 inhibitor, increasing levels of statins, warfarin, and colchicine. Use caution in myasthenia gravis; may exacerbate weakness. QT prolongation risk: avoid use with other QT-prolonging drugs, correct electrolyte abnormalities. For H. pylori eradication, combine with amoxicillin and a PPI as first-line. Renal dose adjustment required for Cr Cl <30 m L/min.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take with or without food, but taking with food may reduce stomach upset.,Complete the full course even if you feel better to prevent resistance.,Avoid grapefruit or grapefruit juice while on this medication.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea/vomiting.,May cause metallic or bitter taste in the mouth; this is usually temporary.,Tell your doctor if you have myasthenia gravis, as clarithromycin can worsen symptoms.,Avoid driving or operating heavy machinery if you experience dizziness or vision changes.,Use effective contraception if applicable; clarithromycin may reduce oral contraceptive efficacy.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIAXIN vs ADDERALL 30, answered by our medical review team.
BIAXIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIAXIN and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIAXIN is: 250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIAXIN and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIAXIN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First t. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.